Summary & Overview
HCPCS Q5158: Denosumab-bnht (bomyntra/conexxence) Injection, 1 mg
HCPCS Level II code Q5158 designates a 1 mg dose of denosumab-bnht (bomyntra/conexxence), a biosimilar denosumab product administered by subcutaneous injection. This code enables payers and providers to classify and bill for the biosimilar formulation of denosumab used in bone-modifying therapy and related indications. Nationally, biosimilar HCPCS codes matter for managing biologic utilization, supply-chain tracking, and payer coverage policies as biosimilars expand therapeutic options and influence cost dynamics.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical and administrative context, typical sites of service, and the common modifiers and billing elements associated with HCPCS Level II injectable biologics. The publication summarizes benchmarks and coverage considerations relevant to billing, documentation, and claims processing for denosumab biosimilars, highlights policy updates affecting biosimilar coding and reimbursement, and provides practical references for payer communications and claim submissions. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code Q5158 represents an injection of denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg. This code describes a single-unit dosage form for a biosimilar of denosumab used in subcutaneous injection therapy.
-
Service type: Injectable biologic therapy (subcutaneous injection)
-
Typical site of service: Outpatient clinics, physician offices, hospital outpatient departments, and infusion/administration centers
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or an adult with cancer-related bone disease who presents to an outpatient infusion clinic or physician office for administration of a denosumab biosimilar, billed as Q5158 (denosumab-bnht, 1 mg). The patient has a documented diagnosis such as osteoporosis, osteopenia with fracture risk, or bone metastases requiring antiresorptive therapy. Pre-visit steps include verification of indications, review of calcium and vitamin D status, and medication reconciliation to identify contraindications (hypocalcemia, pregnancy). At the visit, the clinician documents informed consent, checks pre-procedure vitals, and confirms labs. The medication is prepared by pharmacy or nursing staff, dosed per weight/indication, and administered by subcutaneous injection in the clinic or infusion area. Post-injection monitoring is brief for immediate adverse reactions. Documentation includes drug name and biosimilar identifier, dose (in mg), lot number, route (subcutaneous), site, and any modifier as applicable. Billing uses HCPCS Level II code Q5158 with appropriate modifier(s) to indicate anesthesia, reduced services, or billing circumstance. Typical sites of service are outpatient clinic, physician office, or hospital outpatient department.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / Not commonly used clinically for HCPCS billing |